AIM ImmunoTech reports promising interim data for Ampligen with Keytruda in recurrent ovarian cancer treatment, showing potential for greater effectiveness.
AIM ImmunoTech reports promising interim data for Ampligen combined with Keytruda (pembrolizumab) in recurrent ovarian cancer treatment. The combination therapy shows potential for greater effectiveness than pembrolizumab alone, based on a synergistic effect seen in previous clinical trials with metastatic triple-negative breast cancer, colorectal cancer, and pancreatic cancer. The study is registered at ClinicalTrials.gov under NCT03734692.
April 10, 2024
5 Articles